News from neurorx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 11, 2021, 01:00 ET NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial

NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), and the Quantum Leap Healthcare Collaborative ("Quantum Leap")...


Dec 30, 2020, 01:00 ET NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief") today announced the conclusion of enrollment in the phase 2b/3...


Dec 07, 2020, 01:00 ET NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCQB: RLFTF) ("Relief") today announced that they have met the 165 patient enrollment...


Nov 24, 2020, 10:13 ET NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients

NeuroRx, Inc., and Relief AG (SIX: RLF, OTCQB: RLFTF), announce that more than 175 patients with Critical COVID-19 and Respiratory Failure who also...


Nov 13, 2020, 05:00 ET NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTCBB:RLFTF) ("Relief") announced that as of today, 150 patients (out of a targeted...


Nov 05, 2020, 01:00 ET NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020

NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTCBB:RLFTF) ("Relief") announced that the independent Data Monitoring Committee (DMC)...


Nov 04, 2020, 10:30 ET NeuroRx Receives Notice of Allowance from USPTO for a Formulation for the Treatment of Post-Traumatic Stress Disorder

NeuroRx, Inc. today announced that it has received a notice of patent allowance from the United States Patent and Trademark Office (USPTO) covering a ...


Oct 13, 2020, 01:00 ET NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc., today announced topline results from 45...


Sep 30, 2020, 01:00 ET NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil)

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. have established supply chain agreements and...


Sep 23, 2020, 01:00 ET NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ aviptadil in patients who are...


Mar 26, 2020, 06:28 ET RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress

RELIEF THERAPEUTICS Holding AG (SIX: RLF) "Relief", together with NeuroRx, a Delaware Corporation, have filed an Investigational New Drug (IND)...


Feb 10, 2020, 08:13 ET NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference

NeuroRx will update investors at the upcoming BIO CEO conference on Monday, February 10, 2020 at 10:15am. The company's CEO, Dr. Jonathan Javitt will ...


Oct 23, 2019, 08:36 ET NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101

NeuroRx, Inc (NeuroRx) announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM"), the New York based private alternative...


Jul 09, 2019, 09:46 ET NeuroRx Initiates Pivotal Study for NRX-101, a Breakthrough Designation Therapy Targeting Suicidal Bipolar Depression

NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it has...


Jun 03, 2019, 07:54 ET NeuroRX to Present Phase 2 Efficacy Data for NRX-101 at 2019 BIO International Convention

NeuroRX, a clinical-stage biopharma company developing the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation or Behavior, ...


Jan 03, 2018, 07:55 ET NeuroRx Retains J.P. Morgan as Financial Advisor

NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal...


Dec 27, 2017, 07:30 ET NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)

NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat severe bipolar depression in patients with Acute Suicidal...


Oct 18, 2016, 06:00 ET NeuroRx solidifies Intellectual Property Position - receives notice of Allowance by US Patent Office

NeuroRx, a clinical-stage pharmaceutical company developing NRX-101 (CycluradTM), a first-in-class potentially breakthrough oral drug for the...


Sep 07, 2016, 08:30 ET NeuroRx Announces Participation At The 18th Annual Rodman & Renshaw Global Investment Conference In New York City September 11-13, 2016

NeuroRx, a clinical-stage pharmaceutical company developing CycluradTM, a first-in-class, potentially breakthrough drug for the prevention of suicide ...